An off-switch for drugs' toxic side effects

June 20, 2014 by Angela Herring
Professor Alexandros Makriyannis and his team in the Center for Drug Discovery at Northestern have developed a series of drug compounds that are programmed to break down at a specific time. Credit: Mary Knox Merrill

When medications linger in the human body, they sometimes produce toxic side effects.

Professor Alexandros Makriyannis, the George D. Behrakis Trustee Chair in Pharmaceutical Biotechnology and Director of the Center for Drug Discovery at Northeastern, explained that many things can happen to a drug inside our bodies once it is ingested. For instance, the drug can be modified into other byproducts with their own undesirable and unpredictable effects. Or it can remain embedded in the body's fatty tissues and then be slowly released into the circulatory system.

"If you had a way of controlling how long this drug sits in the body," Makriyannis said, "that would be a beneficial . It would be a safer drug."

In research recently published in the Journal of Medicinal Chemistry and Medicinal Chemistry Letters, Makriyannis and his team present not just one such drug but a whole series of them. "We call this concept controlled deactivation," he explained.

In this research, Makriyannis' team presents more than 100 compounds that are variants of drugs the researchers previously patented. These target the endocannabinoid system, which includes receptors within the surface of cells throughout our bodies that are responsible for functions like pain, mood, memory, and appetite modulation.

The original versions of the new drugs bind to the cannabinoid receptors—which were initially named for their recognition of the tetrahydrocannabinol molecule found in marijuana—and produce some effects such as increased appetite or a sense of euphoria. However, the development of these drugs has been limited by the negative they elicit. In one high-profile case, a cannabinoid antagonist called Acomplia was designed to produce the opposite effects of cannabis. The drug was intended to treat obesity, but was pulled from the market when it was linked to increased suicide rates.

"Our lab works to design and make safer drugs with more controllable action," Makriyannis said. So with funding from the National Institute on Drug Abuse, he and his team set out to develop drugs that feature a timing mechanism that would allow the drug to be deactivated as soon as it has performed its function and be transformed to inactive products.

This timing mechanism, Makriyannis said, is relatively simple—it just takes some very smart and specific chemistry.

The new drugs are chemically modified to be biodegradable and susceptible to particular enzymes in the blood. The enzymes would recognize these drug's new chemical features and "chew them up" right at that spot. The time it takes for the enzymes to finish their action can be controlled, and the resulting byproducts from this enzymatic activity are completely safe, according to Makriyannis.

Additionally, the drugs' chemical modifications ensure they don't stick around in the body's fatty tissues as long, and are thus expelled much more quickly.

"When we started making these new compounds, we weren't sure if they would be successful," Makriyannis said. "But actually, they worked even better than we'd hoped." Not only do the compounds have fewer side effects than the original versions of the drugs, they are also more potent and effective.

While the drugs in the present research all target receptors in the endocannabinoid system, the approach can be applied to virtually any small-molecule drug, Makriyannis said.

"We are controlling the fate of a by just designing these molecules in a manner that allows them to act predictably," he said. "It's a general concept that we've used to make analgesic compounds that are safer and very potent, but the same concept could be used to make neuroprotective drugs or other therapeutic agents."

Explore further: Researchers discover a new anticancer compound using accelerated drug screening process

More information: "Controlled-Deactivation Cannabinergic Ligands." Rishi Sharma, Spyros P. Nikas, Carol A. Paronis, JodiAnne T. Wood, Aneetha Halikhedkar, Jason Jianxin Guo, Ganesh A. Thakur, Shashank Kulkarni, Othman Benchama, Jimit Girish Raghav, Roger S. Gifford, Torbjörn U. C. Järbe, Jack Bergman, and Alexandros Makriyannis. Journal of Medicinal Chemistry 2013 56 (24), 10142-10157. DOI: 10.1021/jm4016075

The report titled "C-Ring Cannabinoid Lactones: A Novel Cannabinergic Chemotype" is available online: pubs.acs.org/doi/pdf/10.1021/ml4005304

Related Stories

New discovery in quest for better drugs

October 14, 2013

Scientists have combined cutting edge computer modelling with pharmacology and medicinal chemistry to reveal new insights into how the body interacts with novel drug treatments, in research that could lead to the creation ...

An end to animal testing for drug discovery?

March 18, 2014

As some countries and companies roll out new rules to limit animal testing in pharmaceutical products designed for people, scientists are stepping in with a new way to test therapeutic drug candidates and determine drug safety ...

Molecular modelling to help create better, safer drugs

May 24, 2013

(Phys.org) —How our bodies break down the common drugs ibuprofen, diclofenac and warfarin is the subject of a new study from the University of Bristol, published in the Journal of the American Chemical Society. The research ...

Recommended for you

Scientific advances can make it easier to recycle plastics

November 17, 2017

Most of the 150 million tons of plastics produced around the world every year end up in landfills, the oceans and elsewhere. Less than 9 percent of plastics are recycled in the United States, rising to about 30 percent in ...

The spliceosome—now available in high definition

November 17, 2017

UCLA researchers have solved the high-resolution structure of a massive cellular machine, the spliceosome, filling the last major gap in our understanding of the RNA splicing process that was previously unclear.

Ionic 'solar cell' could provide on-demand water desalination

November 15, 2017

Modern solar cells, which use energy from light to generate electrons and holes that are then transported out of semiconducting materials and into external circuits for human use, have existed in one form or another for over ...

Pulling iron out of waste printer toner

November 15, 2017

Someday, left-over toner in discarded printer cartridges could have a second life as bridge or building components instead of as trash, wasting away in landfills and potentially harming the environment. One group reports ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.